U.S. Markets closed

Johnson & Johnson (JNJ)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
126.92-0.61 (-0.48%)
At close: 4:02PM EDT
People also watch
PGMRKKOPFEXOM
  • Love JNJ. Put as many eggs as possible in this basket.
  • JNJ may be a compelling opportunity. have you guys heard of awesome-STOCKS. i started receiving their allerts and so far i am happy.
  • When is JNJ going to split?
  • Posted in Geron Corporation

    Johnson & Johnson updates investors today on extensive pipeline of drug candidates, 50+ regulatory filings expected by 2021 https://seekingalpha.com/news/3268041?source=ansh $JNJ

  • Nice upgrade today buy JPM with a target of $140
  • This is on a tear. The people who were hoping to get it cheaper will have to rush in now or just stay out.
  • Any mention of Geron's Imetelstat ?
  • "Lilly Could Grab Diabetes Share From Dow's J&J On Amputation Woes". No wonder it got the upgrade. Or the twerp from JPM is just a nitwit.. I vote nitwit.
  • Better buy GERN while it is on sale Pharmacyclics 58 cents to 252 dollars GERN is next
  • Impressive! Looks like there is still a lot of juice left.
  • TA looks great with potential to begin ripping higher, according to stoxline. On watch for clear above 126.23 with a short term target of 147.44.
  • Mom, Apple Pie, Chevrolet and JNJ.
  • Charles A. Henriques
    NeurogesX Inc.15% owner. QUTENZA developer - Non-Opioid Pain Therapies For Unmet Needs In Neuropathic Pain
    Neuropathic Pain Investor Sacred Heart University Fairfield CT BS/BA Business Administration
    San Francisco Bay Area 500+ 500+ connections
    Charles A. Henriques increased stake in NeurogesX, Inc. Filed SC 13G/A form with U.S. Securities and Exchange Commission on February 13, 2017. Amount beneficially owned: 4,966,649 NGSX shares. CUSIP# 641252101.

    Form 13G is used when the filer owns between 5% and 20% of the company and plans to hold it only as a passive investor. If the filler intend to exert control and if the stake’s size exceeds 20%, then a 13D must be filed. Therefore, activist investors and practices such as: hostile takeovers, company breakups, and other “change of control” events, are not permitted by 13G filers.

    NeurogesX Inc. (NeurogesX), is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, Pain Management Therapies to address unmet medical needs. Qutenza the Company’s first commercial product, has FDA approval, available in USA by Acorda Therapeutics Inc. EU approval in 2009 and available at Astellas Pharma in all 28 European countries.

    Qutenza is a dermal delivery system designed to topically administer capsaicin to treat certain neuropathic pain conditions. Approved by the FDA for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In September 2015, the European Commission approved a label extension for Qutenza to include diabetic patients with neuropathic pain, adding more value to product.

    QUTENZA has a Patented Synthetic Capsaicin that works faster and better than Lyrica according to a study published in the European Journal of Pain, funded by Astellas Pharma Europe Ltd,

    Lyrica is Pfizer’s top selling drug with annual worldwide sales of over $5 billion.

    Grunenthal News 12 -12 -17 Acquiring Commercialization Rights for Qutenza® From Astellas.

    The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany
  • JNJ & PFE both looking to increase revenue going forward, both on their conf. calls stated they need to increase revenue as both fell short. HELLO is anyone out there, BMY ( Bristol Myers ) is for sale. By the way Bristol on their conf. call stated out right that their own EPS & Revenue will increase for 2017. Hmmm, need we say more...
  • Chemo is a $100 Billion dollar industry and one tiny little company threatens to replace it all and every other therapy including radiation with a product that appears to really work far better than anything else EVER and even with very minimal side effects. In fact, at the end of a phase III ten year brain cancer trial where the average patient with chemo lives only 14 months, this new immune therapy has been responsible for more than 100 BRAIN CANCER PATIENTS STILL LIVING AFTER TEN YEARS. OVER 100!

    Fortunate investors will discover this tiny company before final phase III results are released soon.

    This appears to be the big breakthrough in cancer treatment that the world has been looking for for decades.

    https://www.nwbio.com
    Less
    Home - Northwest Biotherapeutics
    Home - Northwest Biotherapeutics
    www.nwbio.com />Less
    Home - Northwest Biotherapeutics
    Home - Northwest Biotherapeutics
    www.nwbio.com

    Home - Northwest Biotherapeutics
    www.nwbio.com
  • JNJ should buy Fitbit.
  • does anyone KNOW if JNJ is a self-insurer or are they covered by insurance for the upcoming slew of jury verdicts in the pending and/or decided talcum powder trials? I realize it will literally take years for the cases to be finally appealed and decided.
  • I'm having trouble believing Baby Powder caused cancer. Wonder if the jury was smoking weed,?
  • What's the new dividend again? I missed it and I can't find a news article yet.
  • Mom, Apple Pie, Chevrolet, and JNJ.